Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk"

Stroke. 2017 Sep;48(9):e256-e257. doi: 10.1161/STROKEAHA.117.018125. Epub 2017 Jul 12.

Authors

Bernard Zinman¹, Silvio E Inzucchi², Hans Christoph Diener³

Affiliations

¹ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
² Section of Endocrinology, Yale University School of Medicine, New Haven, CT.
³ Department of Neurology and Stroke Center, University Hospital Essen, Germany.

PMID: 28701577
DOI: 10.1161/STROKEAHA.117.018125

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Benzhydryl Compounds
Cardiovascular Diseases*
Diabetes Mellitus, Type 2*
Glucosides
Humans
Hypoglycemic Agents
Risk Factors

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
empagliflozin